Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cenix BioScience and Debiopharm Sign Research Agreement

Published: Thursday, May 23, 2013
Last Updated: Thursday, May 23, 2013
Bookmark and Share
Both Companies collaborate to identify predictive biomarkers.

Cenix BioScience and Debiopharm Group™ (Debiopharm) have announced that they have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

Under the research framework’s first project, Cenix will apply its leading expertise in combining high throughput screening with high content assays in cultured human cells, to identify predictive biomarkers for Debiopharm preclinical oncology candidates.

Multi-parametric microscopy-based readouts established by Cenix using the Definiens XD image analysis platform will be used in a range of human cancer cell models to identify genes and pathways that either enhance or suppress the drug’s therapeutic effects.

As such, the study represents another important illustration of Debiopharm’s ongoing drive to integrate cutting edge technologies and powerful post-genomic strategies towards further refining its personalized medicine approach towards the development of new therapeutics.

“We are very excited to launch this new relationship with Debiopharm, extending their repertoire with what we consider to be some of the most strategically powerful cell-based screening paradigms developed to date,” said Dr. Christophe Echeverri, CEO/CSO of Cenix BioScience.

Dr. Echeverri continued, “We deeply appreciate and are particularly gratified by this implied trust from yet another world-class and forward-leaning drug development organization, who also happens to be a long-standing expert in R&D outsourcing”.

“We look forward to working with Cenix, whose specialist expertise, longstanding leadership and unrivaled track record in this field made them an ideal partner,” commented Dr. Hiroaki Tanaka, Director of Personalized Medicine, Debiopharm.

Dr. Tanaka continued, “The opportunity to benefit from such depth of knowledge, experience and extensively validated capabilities is considered as the most strategically important resource for preclinical biomarkers discovery”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quartz Bio Supports Debiopharm Group Precision Medicine Bioinformatics
Debiopharm Group™ have signed a one-year collaboration agreement with Quartz Bio.
Friday, July 05, 2013
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Toxoplasma’s Balancing Act Explained
Parasite’s method of rewiring our immune response leads to novel tool for drug tests.
Cancer Signaling Pathway Illuminating Way To Therapy
Researchers refine a pro-growth signalling pathway, common to cancers, that can kill cancer cells while leaving healthy cells unharmed.
Breast Cancer Cells Starve for Cystine
Depriving triple negative breast cancer, a treatment-resistant form of breast cancer, of cystine results in cancer cell death.
T Cell Channel Could Be Targeted to Treat Cancers
Researcher identify ion-channel found within T cells that could be targeted to reduce development of neck and head cancers.
Novel Urine Test to Predict High-Risk Cervical Cancer
Preliminary studies affirm accuracy and potential cost savings to screen for virus-caused malignancy.
Biomarker Guiding Cancer Therapy
Biologists link levels of Mena protein to breast cancer cells’ sensitivity to chemotherapy.
Protein Array Can Pinpoint Cancer Biomarker
A novel detection method for the detection of glycoproteins has been developed.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!